Latest Eisai Stories

Tokyo, Sept 28, 2011 - (JCN Newswire) - Abbott Japan Co., Ltd. and Eisai Co., Ltd. announced today that they will launch Humira(R) (adalimumab) Prefilled Syringe 20mg/0.4mL, a fully human anti-TNF-α monoclonal antibody for the treatment of polyarticular juvenile idiopathic arthritis (JIA) patients with low body weight, on September 29. Humira Prefilled Syringe 20mg/0.4mL received manufacturing and marketing approval from Japan's Ministry of Health, Labour...

Enters Collaborative Development Agreement with SFJ Pharmaceuticals for Anticancer Agent E7080 (lenvatinib) Tokyo, Sept 7, 2011 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into a collaborative development agreement with SFJ Pharma Ltd. ("SFJ"), a wholly-owned subsidiary of SFJ Pharmaceuticals, LP., II (California), in an effort to further accelerate the late-stage clinical development of its new drug pipeline...

Tokyo, Aug 10, 2011 - (JCN Newswire) - Eisai Co., Ltd. and its diagnostics subsidiary EIDIA Co., Ltd announced today that EIDIA received approval on August 8, 2011 to manufacture and market PROTOCO2L, Japan's first carbon dioxide insufflation system for use as a medical device in CT Colonography, along with the carbon dioxide insufflation tube PROTOCO2L Catheter Set (collectively referred to as "the Product").Carbon dioxide insufflation systems are widely utilized...

Tokyo, July 1, 2011 - (JCN Newswire) - Abbott Japan Co., Ltd. and Eisai Co., Ltd. announced today that they have received approval from Japan's Ministry of Health, Labour, and Welfare (MHLW) for polyarticular juvenile idiopathic arthritis (JIA) as an additional indication of Humira(R) (adalimumab) Pre-filled Syringe 40 mg/0.8 mL for Subcutaneous Injection, a fully human anti-TNF-α monoclonal antibody jointly developed by the two companies in Japan.In...

EXTON, Pa., June 27, 2011 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has successfully completed a campaign to collect 8,792 pounds of food from its employees, more than 5 times as much as it collected last year. With approximately 200 employees at Morphotek, this number equates to over 40 pounds of food donated per employee. The food will be donated to local needy families through collaboration with Philabundance, the area's largest food bank...

EXTON, Pa., April 6, 2011 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it was recently awarded the Beacon Award from CancerCare, a national support services organization for people affected by cancer, for its support of CancerCare's educational programs for people facing lung and ovarian cancers. The two organizations have been working together to help patients and their families become aware of options available to help treat and manage these...

EXTON, Pa., April 4, 2011 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has acquired certain assets relating to a proprietary tumor targeting platform from TransMolecular, Inc. (TMI) for an undisclosed upfront payment and future development milestones. TMI, a biotechnology company headquartered in King of Prussia, PA, developed the tumor-targeting peptide (TTP) platform capable of delivering conjugated radionucleotides, chemotoxins, nanoparticles...

HATFIELD, England, Jan. 25, 2011 /PRNewswire/ -- Eisai announced today that it will submit Marketing Authorization Applications in the United States and the European Union for the investigational compound perampanel (E2007) based on the results of three Phase III pivotal studies. Perampanel is a first-in-class, highly selective non-competitive AMPA-type glutamate receptor antagonist, discovered and being developed by Eisai for adjunctive treatment of partial seizures in patients with...

HATFIELD, England, January 13, 2011 /PRNewswire-FirstCall/ -- - Epilepsy Treatment Zonegran(R) First Commercially Available Product Eisai Europe Limited, a subsidiary of Eisai Co., Ltd (Headquarters: Tokyo; President and CEO: Haruo Naito) announces the establishment of its sales and marketing operation in its wholly owned subsidiary in the Netherlands based in Amsterdam. The first Eisai product on the Dutch market is the epilepsy treatment Zonegran (zonisamide)....

SAN DIEGO and WOODCLIFF LAKE, N.J., Oct. 6, 2010 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Eisai Inc. announced today upcoming lorcaserin presentations at Obesity 2010, the 28th Annual Scientific Meeting of The Obesity Society, in San Diego, California. Lorcaserin, which Arena discovered and developed, is intended for weight management, including weight loss and maintenance of weight loss, in patients who are obese (Body Mass Index, or BMI, >30) or patients who are...